glp-1 receptor agonist with dpp-4 inhibitor combination not recommended Insights into the Roles of GLP-1, DPP-4, and SGLT2 at the Crossroads of Cardiovascular, Renal, and Metabolic Pathophysiology DPP-4 and GLP-1 Combination: Safety
Description
Eli Lilly continues to expand the retatrutide TRIUMPH trial program
The net result is lower blood pressure despite a harder-working heart
Practices may need support with eligibility checks, counselling, monitoring, side effect management and long-term condition reviews
Excessive consumption of caffeinated beverages, including mate, should be avoided to prevent any adverse effects
Nausea rates were similar with both drugs
2021;372:m4573
